Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma

Area of Science:

• Ophthalmology
• Neuroimmunology
• Pharmacology

Background:

• Glaucoma, a leading cause of irreversible vision loss, involves neurodegeneration of retinal ganglionic cells (RGCs).
• Autoimmunity is increasingly recognized as a key factor in RGC death and glaucoma pathogenesis.
• Current treatments primarily manage intraocular pressure (IOP), often failing to halt neurodegeneration, especially in normotensive glaucoma.

Purpose of the Study:

• To explore the potential of cannabinoids as a multitargeted therapeutic strategy for glaucoma.
• To investigate the role of cannabinoids in addressing autoimmunity, neuroinflammation, and neuroprotection in glaucoma.
• To highlight the relevance of cannabinoids in managing glaucoma, particularly in normotensive patients with ongoing RGC degeneration.

Main Methods:

• Review of existing literature on glaucoma, autoimmunity, and cannabinoid pharmacology.
• Analysis of cannabinoid mechanisms including neuroprotective, anti-inflammatory, and immunosuppressive effects.
• Examination of the gut-retina axis and Wnt signaling pathways in relation to glaucoma and cannabinoid action.

Main Results:

• Cannabinoids possess multifaceted properties beneficial for glaucoma, including IOP reduction, neuroprotection, and anti-inflammatory effects.
• Cannabinoids modulate immune responses and exhibit epigenetic effects on immune cells involved in autoimmunity.
• Evidence suggests cannabinoids can target multiple pathways implicated in glaucomatous neurodegeneration.

Conclusions:

• Cannabinoids represent a promising multitargeted approach for glaucoma treatment, particularly for autoimmune-related neurodegeneration.
• This strategy may offer new therapeutic avenues for normotensive glaucoma patients experiencing silent RGC loss.
• Further research into cannabinoid-based therapies could revolutionize glaucoma management by addressing its complex etiopathology.